Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation
01 févr. 2024 03h00 HE
|
Cumulus Oncology
Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation Newly appointed CEO, Dr Xavier Leroy, will...
Cumulus Oncology raises £9m in seed financing
08 janv. 2024 02h00 HE
|
Cumulus Oncology
Cumulus Oncology raises £9m in seed financing Eos Advisory-led round includes new corporate investor the Scottish National Investment Bank Proceeds from the financing will be used to support Cumulus...
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
17 juil. 2023 02h00 HE
|
Cumulus Oncology
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets Resulting IP will be licensed into a newly created Cumulus company ...
LDC and Cumulus Oncology announce collaboration
22 mars 2021 04h00 HE
|
Cumulus Oncology
LDC and Cumulus Oncology announce collaboration Dortmund, Germany, and Edinburgh, Scotland, March 22nd, 2021. The Lead Discovery Center GmbH (LDC) and Cumulus Oncology announce the signing of a...
Modulus Oncology Appoints Tim Edwards as Chairman
11 janv. 2021 07h00 HE
|
Modulus Oncology
Modulus Oncology Appoints Tim Edwards as Chairman Sheffield, UK, 11 January 2021: Modulus Oncology, a new and rapidly emerging private biotech company focused on treating hard-to-treat cancers,...
Modulus Oncology Appoints Tim Edwards as Chairman
11 janv. 2021 02h00 HE
|
Modulus Oncology
Modulus Oncology Appoints Tim Edwards as Chairman Sheffield, UK, 11 January 2021: Modulus Oncology, a new and rapidly emerging private biotech company focused on treating hard-to-treat cancers,...
University of Sheffield spin-out Modulus Oncology to advance new drug targeting hard-to-treat cancers
09 sept. 2020 02h00 HE
|
Modulus Oncology
University of Sheffield spin-out Modulus Oncology to advance new drug targeting hard-to-treat cancers First-in-class drug blocks key signals required for tumour growth and metastasisHighly...